Our Center is participating in a study on Aerosolized antibiotics, which as a mist directly into the lungs have been shown to improve lung function and decrease the amount of bacteria found in the sputum (phlegm). TOBI, Tobramycin solution for inhalation, is an aerosolized antibiotic that has been approved by the Food and Drug Administration (FDA) for use by patients with CF in children ages 6–15.
Children who participate in this study are randomly assigned to receive either Tobramycin solution for inhalation or standard care. There are about 400 patients participating in this study.
At the first visit of this study, a CF doctor will determine if your child is eligible to participate based on a number of criteria, including pulmonary function tests. Children are required to return to the clinic two months after the first study visit, and every three months thereafter, for a total of six visits over 14 months.
Study Title: An Open–Label Randomized Trial with Tobramycin Solutionfor Inhalation (TOBI) in Cystic Fibrosis Patients with Mild Lung Disease PC–TNDS–009